Press-release for stocks published on this month for novartis ag

published : This month entities : Novartis ag

save search

Viral Vector and Plasmid DNA Technologies: A Global Market Perspective
Published: 2024-04-17 (Crawled : 10:00) - prnewswire.com
TMO | News | $544.78 0.6% 0.0% 1.7M

Health Technology

| -2.24% | O: -0.26% H: 0.03% C: -1.55%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| 1.66% | O: 0.87% H: 0.16% C: -0.59%
RGNX | $15.67 -2.73% -2.87% 570K

Health Technology

| -12.08% | O: -1.43% H: 2.27% C: -3.18%
global dna market

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Published: 2024-04-17 (Crawled : 06:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| 1.66% | O: 0.87% H: 0.16% C: -0.59%
kesimpta sclerosis novartis show benefits

Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Published: 2024-04-16 (Crawled : 14:00) - prnewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M

Health Technology

| -0.62% | O: -0.53% H: 0.0% C: -1.24%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| 0.17% | O: -1.46% H: 0.0% C: 0.0%
PHG | $19.98 0.0% 540K

Health Technology

| -3.34% | O: -1.21% H: 0.0% C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M

Health Technology

| -1.85% | O: -1.19% H: 0.52% C: -0.17%
VRNA | $15.82 -1.74% -1.83% 640K

Health Technology

| -0.51% | O: 1.65% H: 2.43% C: 0.87%
reach treatment research market

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| 0.17% | O: -1.46% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K

Health Technology

| -1.99% | O: -1.94% H: 0.43% C: -0.34%
OCUL | $5.22 -10.92% -12.26% 9.1M

Health Technology

| -32.56% | O: -1.03% H: 3.66% C: 1.7%
ocular key leaders

Biologic Therapeutics Market size is set to grow by USD 286.12 billion from 2023-2027, Introduction of biosimilars boost the market, Technavio
Published: 2024-04-15 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -0.29% | O: -1.75% H: 0.85% C: 0.85%
AZNCF | News | $138.24 -4.19% 800

Health Technology

| 0.19% | O: 2.1% H: 0.0% C: -2.52%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| 0.17% | O: -1.46% H: 0.0% C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M

Health Technology

| -1.85% | O: -1.19% H: 0.52% C: -0.17%
BAX | $39.47 -0.45% 0.0% 2.8M

Health Technology

| -1.42% | O: -0.1% H: 0.13% C: -1.08%
ABBV | $166.41 1.06% 0.0% 5.5M

Health Technology

| 2.93% | O: 0.32% H: 0.96% C: 0.22%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -1.22% | O: -2.13% H: 0.0% C: 0.0%
BMRN | $88.68 -1.54% -1.57% 1.8M

Health Technology

| -3.15% | O: -0.72% H: 0.0% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| -0.26% | O: -0.64% H: 0.45% C: -0.04%
AMGN | $269.03 2.39% 2.33% 3.4M

Health Technology

| 1.29% | O: 0.41% H: 0.0% C: 0.0%
set therapeutics market

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Published: 2024-04-15 (Crawled : 18:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| 0.17% | O: -1.46% H: 0.0% C: 0.0%
fabhalta nephropathy for novartis show

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -0.22% | O: 0.32% H: 0.04% C: -0.56%
ARVN | $34.78 1.43% 1.41% 940K

Health Technology

| -3.9% | O: 8.28% H: 0.56% C: -4.75%
arv-766 protac license cancer treatment global protein for commercialization agreement

Novartis tender offer for MorphoSys AG commences
Published: 2024-04-11 (Crawled : 09:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K

Health Technology

| -0.49% | O: -0.32% H: 0.48% C: -0.17%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -0.22% | O: 0.32% H: 0.04% C: -0.56%
MOR | News | $17.96 -0.5% -0.5% 180K

Health Technology

| -0.08% | O: 0.69% H: 0.0% C: -0.39%
for novartis

Central Nervous System (CNS) Stimulant Drugs Market size is set to grow by USD 6.48 billion from 2023-2027, Rise in incidence of CNS disorders boost the market, Technavio
Published: 2024-04-10 (Crawled : 09:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K

Health Technology

| -9.51% | O: -100.0% H: NaN% C: Infinity%
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.65% | O: -0.01% H: 0.0% C: 0.0%
NVSEF | $93.6375 6.88% 82K

Health Technology

| -2.16% | O: -1.67% H: 0.0% C: 0.0%
ALPMY | $9.47 -1.11% 520K

Manufacturing

| -9.26% | O: -0.29% H: 0.0% C: -1.97%
VTRS A | $11.25 1.17% 1.16% 4.7M

Health Technology

| -4.01% | O: -0.6% H: 1.03% C: 0.52%
TMO | News | $544.78 0.6% 0.0% 1.7M

Health Technology

| -7.54% | O: -2.01% H: 0.0% C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -1.37% | O: -1.16% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -2.59% | O: -0.32% H: 0.0% C: 0.0%
JAZZ | $109.96 0.63% 0.63% 760K

Health Technology

| -4.92% | O: -1.71% H: 0.57% C: 0.37%
disorders system set market

Eczema Therapeutics Market size is set to grow by USD 5.81 bn from 2024-2028,high prevalence of atopic dermatitis boost the market- Technavio
Published: 2024-04-08 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| 0.01% | O: 2.24% H: 0.0% C: -0.8%
AZNCF | News | $138.24 -4.19% 800

Health Technology

| 2.24% | O: -3.43% H: 6.21% C: 6.21%
VTRS A | $11.25 1.17% 1.16% 4.7M

Health Technology

| -4.66% | O: -0.25% H: 1.1% C: -0.17%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -1.49% | O: -0.05% H: 0.43% C: -0.27%
BMY | $48.93 1.3% 0.0% 10M

Health Technology

| -4.66% | O: -0.08% H: 0.04% C: -0.35%
BHC | $8.69 1.05% 0.0% 2.9M

Health Technology

| -16.52% | O: 0.38% H: 0.0% C: -7.27%
ABBV | $166.41 1.06% 0.0% 5.5M

Health Technology

| -0.9% | O: 0.77% H: 1.63% C: 0.35%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -1.33% | O: 0.84% H: 0.0% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 1.63% | O: 0.18% H: 0.3% C: 0.19%
eczema dermatitis set therapeutics market

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
Published: 2024-04-06 (Crawled : 20:20) - globenewswire.com
NVSEF | $93.6375 6.88% 82K

Health Technology

| Email alert Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| Email alert Add to watchlist
leqvio novartis therapy show

Positron Emission Tomography Market size is set to grow by USD 725.97 mn from 2024-2028,increasing prevalence of chronic conditions worldwide boost the market- Technavio
Published: 2024-04-03 (Crawled : 06:00) - prnewswire.com
CAJPY | $28.42 -0.41% 29K

n/a

| -4.6% | O: -0.3% H: 0.54% C: 0.54%
CAJFF | $29.0664 -28.15% 760

Electronic Technology

| -2.61% | O: -100.0% H: NaN% C: Infinity%
NVSEF | $93.6375 6.88% 82K

Health Technology

| -1.43% | O: -2.86% H: 0.17% C: 0.17%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -0.05% | O: 0.04% H: 0.46% C: -0.08%
PHG | $19.98 0.0% 540K

Health Technology

| 0.3% | O: 1.0% H: 0.0% C: 0.0%
worldwide set market

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
NAMS | $19.98 2.78% 2.7% 140K

n/a

| -11.05% | O: 6.23% H: 2.77% C: -10.21%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -2.1% | O: 0.47% H: 0.23% C: -0.99%
pharma business

Carisma Therapeutics Announces Changes to its Board of Directors
Published: 2024-04-01 (Crawled : 11:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -2.1% | O: 0.47% H: 0.23% C: -0.99%
CRIS | $14.59 -4.14% -4.32% 10K

Health Technology

| 32.81% | O: 0.7% H: 16.87% C: 16.87%
therapeutics

published : This month entities : Novartis ag

save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

published : This month entities : Novartis ag save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

published : This month entities : Novartis ag

save search